Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India

Author(s): Tirthankar Deb*, Rajesh Garg, Manmeet Kaur, Ankita Beniwal and Varsha Gupta

Volume 17, Issue 4, 2022

Published on: 28 March, 2022

Page: [344 - 349] Pages: 6

DOI: 10.2174/1574886317666220113101815

Price: $65

Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). Though many classes of drugs have been advocated/used for the treatment of this disease, vaccines are being targeted for its ultimate prevention. Indian Government has approved Covishield (ChAdOx1 nCoV19 Corona Virus Vaccine-Recombinant) for restricted use in emergency circumstances.

Objective: This study is aimed at evaluating the safety profile of the Covishield vaccine among healthcare workers in a tertiary care hospital.

Methods: All Adverse Drug Reactions (ADRs) reported to the ADR monitoring centre by healthcare workers who received the Covishield vaccine during the study period of 3 months were analysed on various parameters, and the assessment was done using the WHO-UMC scale.

Results: During the study period, a total of 1216 beneficiaries were vaccinated with 1st dose of Covishield, and out of these, 727 beneficiaries also received 2nd dose of the vaccine. Out of the 1216 beneficiaries vaccinated, 69 ADRs were reported in 24 healthcare workers. The most common ADR reported was fever (24.64%), followed by myalgia (18.84%). No death or any serious anaphylactic reaction was observed. None of the healthcare workers experienced any adverse event during the observation period of 30 minutes. Serious reactions were reported in 4 healthcare workers as per the Pharmacovigilance Programme of India (PvPI) criteria of serious AEFI. 92% of healthcare workers recovered from ADRs during the study period. 84% of ADRs were classified as probable as per the WHO-UMC scale.

Conclusion: As per the Government of India directives, all the healthcare workers in the institute were encouraged to take both doses of the Covishield vaccine. The beneficiaries were kept under observation for 30 minutes and monitored for any adverse drug reaction following vaccination. The vaccine was found to be safe with a very low incidence of ADRs.

Keywords: Covishield, COVID-19, healthcare workers, ADRs, vaccination, beneficiaries.

« Previous Next »
Graphical Abstract

[1]
Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020; 13(5): 667-73.
[http://dx.doi.org/10.1016/j.jiph.2020.03.019] [PMID: 32340833]
[2]
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents 2020; 55(5): 105951.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105951] [PMID: 32234466]
[3]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 324(8): 782-93.
[http://dx.doi.org/10.1001/jama.2020.12839] [PMID: 32648899]
[4]
Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[5]
Goel A, Mittal R. Beniwal. A coronavirus: Genetic organization, infestation, pathophysiological impacts, diagnostics and therapeutics in COVID-19. JOHP 2020; 15(4): 1.
[6]
Serum institute of India. India: Fact sheet covishield 2021 2021. Available from: https://www.seruminstitute.com/product_covishield.php
[7]
Ophinni Y, Hasibuan AS, Widhani A, et al. COVID-19 vaccines: Current status and implication for use in Indonesia. Acta Med Indones 2020; 52(4): 388-412.
[PMID: 33377885]
[8]
COVID-19 vaccination drive to begin from January 16 in India. India: Hindustan Times 2021 2021. Available from: https://www.hindustantimes.com/india-news/covid19-vaccination-drive-to-begin-in-india-from-january-16-says-centre-101610189889889.html
[9]
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396(10249): 467-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31604-4]
[10]
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395(10240): 1845-54.
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3]
[11]
Kim S, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: A single center experience. J Korean Med Sci 2021; 36(14): e107.
[12]
Voysey M, Ann S, Clemens C, Madhi SA, Weckx LY, Folegatti PM. Articles safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy